LLY

936.27

+3.59%↑

JNJ

186.18

-0.33%↓

UNH

326.77

-1.02%↓

NVS

125.53

+0.57%↑

ABT

124.35

-0.77%↓

LLY

936.27

+3.59%↑

JNJ

186.18

-0.33%↓

UNH

326.77

-1.02%↓

NVS

125.53

+0.57%↑

ABT

124.35

-0.77%↓

LLY

936.27

+3.59%↑

JNJ

186.18

-0.33%↓

UNH

326.77

-1.02%↓

NVS

125.53

+0.57%↑

ABT

124.35

-0.77%↓

LLY

936.27

+3.59%↑

JNJ

186.18

-0.33%↓

UNH

326.77

-1.02%↓

NVS

125.53

+0.57%↑

ABT

124.35

-0.77%↓

LLY

936.27

+3.59%↑

JNJ

186.18

-0.33%↓

UNH

326.77

-1.02%↓

NVS

125.53

+0.57%↑

ABT

124.35

-0.77%↓

Kodu・Aktsiate loetelu・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Avatud

SektorTervishoid

46.48 1.8

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

45.38

Max

46.6

Põhinäitajad
By Trading Economics
Sissetulek	882M 2.2B
Müük	-47M 12B
P/E Sektori keskmine	15.495 77.256
Aktsiakasum	1.46
Dividenditootlus	5.38
Kasumimarginaal	17.959
Töötajad	34,100
EBITDA	820M 4.1B

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+15.07% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	5.38% 2.33%

Turustatistika
By TradingEconomics
Turukapital	4.5B 94B
Eelmine avamishind	44.68
Eelmine sulgemishind	46.48

Uudiste sentiment

By Acuity

50%

153 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

N/A / 50.57 Toetus ja vastupanu

Bristol-Myers Squibb Co. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. okt 2025, 11:14 UTC

Tulu

Bristol Myers Squibb 3Q Profit Soars, Raises Revenue Guidance

10. okt 2025, 12:32 UTC

Omandamised, ülevõtmised, äriostud

Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion

31. juuli 2025, 11:14 UTC

Tulu

Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q

30. okt 2025, 16:52 UTC

Omandamised, ülevõtmised, äriostud

Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera -- WSJ

30. okt 2025, 16:52 UTC

Omandamised, ülevõtmised, äriostud

Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ

30. okt 2025, 11:32 UTC

Tulu

Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain. -- Barrons.com

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis, Which Was More Than Offset by Expected Continued Generic Impact Across Remainder of Legacy Portfolio >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: Revised 2025 Adj EPS Guidance Inclusive of 80c Loss Per Shr Net Impact Related to Acquired IPRD Charges and Licensing Income >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 3Q Adjusted Gross Margin 72.9% >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 3Q U.S. Revenue Rose 1% to $8.33B >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb Raises 2025 Rev Guidance to $47.5B-$48B Vs Prior Outlook $46.5B-$47.5B >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: Raised 2025 Rev Guidance Primarily Reflects Continued Strong Performance of Growth Portfolio >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 3Q International Revenue Rose 6% to $3.89B >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: 3Q Growth Portfolio Revenue Increase Primarily Driven by Immuno-Oncology Portfolio, Reblozyl, Camzyos and Breyanzi >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 3Q Legacy Portfolio Rev Fell 12% to $5.37B >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb Adjusts 2025 View To Adj EPS $6.40-Adj EPS $6.60 Vs Prior Outlook $6.35-$6.65 >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 3Q Gross Margin 71.9% >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 3Q Growth Portfolio Revenue Rose 18% to $6.86B >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: Latest 3Q Includes Net Impact of Loss of 20c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 3Q Adj EPS $1.63 >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 3Q Rev $12.22B >BMY

30. okt 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 3Q EPS $1.08 >BMY

10. okt 2025, 16:19 UTC

Omandamised, ülevõtmised, äriostud

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

10. okt 2025, 11:02 UTC

Omandamised, ülevõtmised, äriostud

Bristol-Myers Squibb to Pay $1.5B in Cash at Closing to Acquire Orbital >BMY

10. okt 2025, 11:01 UTC

Omandamised, ülevõtmised, äriostud

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio With Acquisition of Orbital Therapeutics

4. aug 2025, 11:59 UTC

Tulu

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

31. juuli 2025, 11:54 UTC

Tulu

Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 2Q Growth Portfolio Revenue Rose 18% to $6.6B >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb Cuts 2025 View To Adj EPS $6.35-Adj EPS $6.65 Vs Prior View $6.70-$7.00 >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 2Q Adjusted Gross Margin 72.6% >BMY

Võrdlus sarnastega

Hinnamuutus

Bristol-Myers Squibb Co. Prognoos

Hinnasiht

By TipRanks

15.07% tõus

12 kuu keskmine prognoos

Keskmine 52.46 USD 15.07%

Kõrge 65 USD

Madal 36 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Bristol-Myers Squibb Co. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

16 ratings

Osta

Hoia

Müü

Põhineb 16 analüütiku instrumendi Bristol-Myers Squibb Co. aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 50.57Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

153 / 373 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.